Cutler Group’s Relmada Therapeutics RLMD Stock Holding History

Cutler Group’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-600	Closed	-$3K	–	4247
2023 Q2	$3K	Hold	600	–	–	﹤0.01%	2896
2023 Q1	$3K	Sell	600 -15,000	-96%	-$51.7K	﹤0.01%	3010
2022 Q4	$26K	Buy	15,600 +11,600	+290%	+$102K	﹤0.01%	2037
2022 Q3	$26K	Sell	4,000 -8,000	-67%	-$222K	﹤0.01%	2412
2022 Q2	$9K	Sell	12,000 -18,200	-60%	-$397K	﹤0.01%	3299
2022 Q1	$43K	Buy	+30,200	New	+$624K	﹤0.01%	2387
2021 Q4	–	Sell	-3,000	Closed	-$6K	–	5939
2021 Q3	$6K	Buy	+3,000	New	+$80.3K	﹤0.01%	4353
2021 Q1	–	Sell	-2,300	Closed	-$14K	–	6172
2020 Q4	$14K	Buy	2,300 +1,600	+229%	+$55K	﹤0.01%	2943
2020 Q3	$8K	Sell	700 -300	-30%	-$11.6K	﹤0.01%	3164
2020 Q2	$3K	Buy	+1,000	New	+$42.3K	﹤0.01%	3646
2020 Q1	–	Sell	-500	Closed	-$1K	–	4537
2019 Q4	$1K	Buy	+500	New	+$15.2K	﹤0.01%	3747

Other funds holding RLMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cutler Group's RLMD Position: Q1 2024 in Review

Cutler Group reduced its Relmada Therapeutics (RLMD) stake by 3.2% in Q1 2024, selling an estimated $1.45K and leaving 9,000 shares worth $41K. The position accounts for 0.01% of the portfolio, ranked #756.

Cutler Group first reported a position in RLMD in Q1 2020 and has held it in 16 quarters since. The position peaked at $388K in Q3 2022. 93 funds tracked by Wall St. Rank hold RLMD as of Q1 2024.

Cutler Group held 9,000 shares of Relmada Therapeutics worth $41K as of Q1 2024.
Cutler Group sold 300 Relmada Therapeutics shares in Q1 2024, an estimated $1.45K.
Relmada Therapeutics made up 0.01% of Cutler Group's portfolio in Q1 2024, its #756 holding.
Cutler Group first reported a position in Relmada Therapeutics in Q1 2020 and has held it in 16 quarters since.
Cutler Group's Relmada Therapeutics position peaked at $388K in Q3 2022.
93 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.